Xilio Therapeutics Announces XTX501 Shows Robust Monotherapy Activity; Plans IND Submission In Middle Of 2026; Intends To Start Phase 1 Study Of XTX501 In H2 This Year

Xilio Therapeutics, Inc. (Nasdaq: XLO) announced that its candidate XTX501 showed robust monotherapy activity in preclinical studies and plans to submit an investigational new drug (IND) application in mid-2026. The company intends to start a Phase 1 trial for XTX501 in the second half of 2026, with initial data expected in the second half of 2027, pending FDA clearance. XTX501 will initially target patients with metastatic non-small cell lung cancer, with potential expansion to other solid tumors.